Exone-A (HK inno.N Corporation)

**Exone-A** is an oral fixed-dose combination small-molecule tablet developed by **HK inno.N** for patients with **hypertension and dyslipidemia**. Public sources identify it as a three-drug combination containing **amlodipine**, **valsartan**, and **atorvastatin**, corresponding to the sponsor development code **CJ-30061** in a clinical pharmacokinetic study. Its therapeutic rationale is complementary cardiovascular risk control: amlodipine blocks L-type calcium channels to reduce vascular smooth-muscle tone, valsartan antagonizes the angiotensin II type 1 receptor to inhibit the renin-angiotensin system and lower blood pressure, and atorvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis and improve lipid parameters. HK inno.N lists Exone-A in its pipeline/product materials for hypertension with dyslipidemia and indicates an NDA/BLA-stage commercial program.

Brand names

Exone-A

Other names

amlodipine + valsartan + atorvastatin